← Eichor
Condition: Relapsed Or Refractory Multiple Myeloma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsed Or Refractory Multiple Myeloma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or R
Phase 3 · 1 location(s) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. · NCT07452198A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07255898A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Phase 1 · 1 location(s) · Alfred Chung, MD · NCT06348108Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Ag
Phase 1 · 27 location(s) · AbbVie · NCT06896916A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidos
Phase 1/Phase 2 · 20 location(s) · Regeneron Pharmaceuticals · NCT06292780A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments
Phase 1/Phase 2 · 17 location(s) · Bristol-Myers Squibb · NCT05372354Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 4 location(s) · Zhejiang ACEA Pharmaceutical Co. Ltd. · NCT05565807A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT07609030CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04603872A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
Phase 3 · 266 location(s) · Celgene · NCT05519085Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Phase 1 · 14 location(s) · National Cancer Institute (NCI) · NCT06465316A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
Phase 3 · 109 location(s) · Janssen Research & Development, LLC · NCT07258511A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in
Phase 1 · 2 location(s) · Mayo Clinic · NCT03017820A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Ref
Phase 1 · 5 location(s) · Hoffmann-La Roche · NCT06934044Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Phase 1 · 5 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT07529782A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Partici
Phase 2 · 34 location(s) · Sanofi · NCT06356571A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamet
Phase 3 · 242 location(s) · Janssen Research & Development, LLC · NCT06208150A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 1 · 3 location(s) · Zhejiang University · NCT06644118Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Particip
Phase 3 · 166 location(s) · AbbVie · NCT06158841A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in R
Phase 3 · 12 location(s) · Hangzhou Sumgen Biotech Co., Ltd. · NCT06508983OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Phase 1/Phase 2 · 5 location(s) · OriCell Therapeutics Co., Ltd. · NCT06182696Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1 · 1 location(s) · O&D BioTech Group CO., Limited · NCT07369895Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Phase 2 · 20 location(s) · CellCentric Ltd. · NCT07096778MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Ha
Phase 3 · 271 location(s) · Pfizer · NCT06152575Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1 · 12 location(s) · Opna Bio LLC · NCT06433947A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Partic
Phase 1 · 14 location(s) · Genentech, Inc. · NCT05927571A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed a
Phase N/A · 1 location(s) · iOMEDICO AG · NCT07559799A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 · 29 location(s) · Janssen Research & Development, LLC · NCT07518186
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.